secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001683168-24-007713
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio reports Phase 1b data: complete & partial responses in cutaneous SCC patients
--------------------------------------------------------------------------------

- Intratumoral PH-762 well tolerated with no related adverse events or dose-limiting toxicities across 5 patients.
- Cohort 2: 1 complete response (100% tumor clearance) and 1 partial response (90% tumor clearance) in cutaneous squamous cell carcinoma.
- Phase 1b trial ongoing; enrollment anticipated to complete in Q3 2025.
- Data presented at SITC 2024 annual meeting in Houston, TX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824007713/0001683168-24-007713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824007713/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-007713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer